GENEVA–( )–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceutical drugs, Inc. (NASDAQ: AERI, “Aerie”). This transaction helps bolster Alcon’s presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pipeline.

“As we welcome the particular Aerie team to Alcon, we look forward to leveraging our expanding commercial footprint plus expertise in order to bring Rocklatan ® and Rhopressa ® to even more customers and their patients, ” said David Endicott, CEO of Alcon. “Alcon has a rich history in the ophthalmic pharmaceutical space rooted within a deep understanding associated with Eye Care Professionals. We are excited to add Aerie’s significant technical expertise to Alcon R& D, which enhances our own efforts to build a compelling portfolio of ophthalmic pharmaceuticals. ”

Through the transaction, Alcon has added the industrial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0. 02%/0. 005% plus Rhopressa (netarsudil ophthalmic solution) 0. 02%, as well as AR-15512, the Phase 3 product candidate for dry eye disease. Alcon has also acquired a pipeline associated with ophthalmic pharmaceutic product candidates with the opportunity to leverage Aerie’s existing research and development capabilities.

The deal complements Alcon’s expansion into the ophthalmic pharmaceutical area, including acquisitions of the exclusive U. S. commercialization rights for Simbrinza ® from Novartis in April 2021 and Eysuvis ® plus Inveltys ® from Kala Drugs, Inc. in May 2022.

Alcon intends to fully integrate Aerie into its business. As previously disclosed, the Company has used debt to fund the particular transaction for a total purchase consideration of approximately $930 million.

J. P. Morgan acted as Alcon’s financial advisor for the transaction, and Alcon’s legal advisor was Skadden, Arps, Slate, Meagher & Flom LLP. Goldman Sachs & Co. LLC and Lazard served as Aerie’s financial advisors for that deal, and Aerie’s legal consultant was Fried, Frank, Harris, Shriver & Jacobson LLP.

About Alcon

Alcon helps people observe brilliantly. Because the worldwide leader in eye treatment with the heritage spanning over 75 years, all of us offer the broadest portfolio of products to enhance sight plus improve people’s lives. Our Surgical and Vision Treatment products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases plus refractive errors. Our a lot more than 24, 000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access in order to quality eye care. Learn more at www.alcon.com .

References

  1. Ophthalmology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain “forward-looking statements” within the particular meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate, ” “intend, ” “commitment, ” “look forward, ” “maintain, ” “plan, ” “goal, ” “seek, ” “target, ” “assume, ” “believe, ” “project, ” “estimate, ” “expect, ” “strategy, ” “future, ” “likely, ” “may, ” “should, ” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we all make regarding our liquidity, revenue, gross margin, operating margin, effective tax rate, foreign currency exchange movements, earnings per share, our plans and decisions relating to various capital expenditures, capital allocation priorities plus other discretionary items such as the transformation program, market growth assumptions, the acquisition associated with Aerie, and generally, our expectations concerning our long term performance plus the effects of the COVID-19 pandemic on our businesses.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our own current beliefs, expectations and assumptions concerning the upcoming of the business, future plans plus strategies, and other long term conditions. Because forward-looking claims relate to the future, they are subject to inherent uncertainties and risks that are usually difficult to predict like: cybersecurity breaches or other disruptions of our information technology systems; compliance along with data privacy, identity protection and info security laws; our ability to comply with the US Foreign Corrupt Practices Act associated with 1977 plus other applicable anti-corruption laws and regulations, particularly given that we have entered into a three-year Deferred Prosecution Agreement with the U. S. Department of Justice; our success in completing and integrating strategic purchases; our ability to execute and achieve the expected benefits of our transformation program; anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, income, synergies, economic performance, indebtedness, financial condition, losses, future prospects, and business and management strategies for the particular Aerie transaction; transaction costs from the Aerie transaction; the impact associated with a disruption in our global supply chain or even important facilities; the effect of the COVID-19 pandemic as well as other viral or disease outbreaks; global and regional financial, financial, legal, tax, political and social change; Russia’s war on Ukraine and the resulting global response; the particular commercial achievement of our own products and the capability to maintain and strengthen our position in our markets; the success of our r and d efforts, including our own ability to innovate to compete effectively; pricing pressure through changes inside third party payor coverage plus reimbursement methodologies; ongoing industry consolidation; the capability to properly educate and train healthcare providers upon our items; the impact of unauthorized importation in our products from countries along with lower prices to nations with higher prices; our reliance on outsourcing key business functions; changes within inventory levels or buying patterns of our own customers; our own ability in order to attract plus retain qualified personnel; the ability to service our financial debt obligations; the need with regard to additional financing through the issuance of debt or equity; our capability to protect our intellectual property; the effects of litigation, including product liability lawsuits and governmental investigations; our capability to comply with all laws to which we may be subject; effect of product recalls or voluntary market withdrawals; the implementation of our enterprise resource planning system; the accuracy of our accounting estimates plus assumptions, which includes pension and other post-employment benefit plan obligations as well as the carrying value of intangible assets; the ability to obtain regulatory clearance and approval of our own products as well as compliance along with any post-approval obligations, including quality control of the manufacturing; legislative, tax plus regulatory reform; the capability of Alcon Pharmaceuticals Ltd. to comply with the investment tax incentive agreement with the particular Swiss State Secretariat regarding Economic Affairs in Switzerland and the Canton of Fribourg, Switzerland; our ability to manage environmental, social and governance matters to the satisfaction of our own many stakeholders, some of which may have competing interests; the impact of being listed upon two stock exchanges; the ability to declare and pay dividends; the different privileges afforded in order to our shareholders as the Swiss corporation compared to a U. H. corporation; plus the a result of maintaining or even losing the foreign private issuer status under Circumstance. S. securities laws.

Additional factors are discussed within our filings using the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these questions or dangers materialize, or should underlying assumptions prove incorrect, actual results might vary materially from those anticipated. Therefore , you should not rely on any associated with these forward-looking statements. Forward-looking statements in this press release speak just as of the particular date of its filing, and all of us assume no obligation to update forward-looking statements because a result of new information, upcoming events or otherwise.

Connect with us on

Facebook
LinkedIn

Leave a Reply

Your email address will not be published. Required fields are marked *